High dose atorvastatin decreases cellular markers of immune activation without affecting HIV-1 RNA levels: Results of a double-blind randomized placebo controlled clinical trial

Journal of Infectious Diseases

Volumn 203, Issue 6, 2011, Pages 756-764

  Ganesan, Anuradha ^a   Crum Cianflone, Nancy ^a,b   Higgins, Jeanette ^c   Qin, Jing ^d   Rehm, Catherine ^d   Metcalf, Julia ^d   Brandt, Carolyn ^b   Vita, Jean ^a   Decker, Catherine F ^a   Sklar, Peter ^e,f   Bavaro, Mary ^b   Tasker, Sybil ^g   Follmann, Dean ^d   Maldarelli, Frank ^h  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b NAVAL MEDICAL CENTER SAN DIEGO   (United States)

^c SAIC FREDERICK INC   (United States)

^d NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^e DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f MERCK RESEARCH LABORATORIES   (United States)

^g Pharmaceutical Product Development   (United States)

^h NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; CD38 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CELL MARKER; HLA DR ANTIGEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIGEN EXPRESSION; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNOSTIMULATION; LYMPHOCYTE COUNT; MALE; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; T LYMPHOCYTE ACTIVATION; TREATMENT DURATION; TREATMENT OUTCOME;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; HEPTANOIC ACIDS; HIV INFECTIONS; HIV-1; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; PLACEBOS; PYRROLES; RNA, VIRAL;

EID: 79952341800     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jiq115     Document Type: Article

References (49)

1. Johnson JA, Li JF, Wei X, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5:e158.
2. Deeks SG. Immune dysfunction, inflammation, and accelerated aging in patients on antiretroviral therapy. Top HIV Med 2009; 17:118-23.
3. Friis-Moller N, Reiss P, Sabin CA, et al. Class of antiretroviral drugs and the risk of myocardial infarction. N Engl J Med 2007; 356:1723-35. (Pubitemid 46658704)
4. Pike LJ. Rafts defined: a report on the Keystone Symposium on Lipid Rafts and Cell Function. J Lipid Res 2006; 47:1597-8. (Pubitemid 44079915)
5. Ono A, Freed EO. Plasma membrane rafts play a critical role in HIV-1 assembly and release. Proc Natl Acad Sci U S A 2001; 98:13925-30. (Pubitemid 33116000)
6. del Real G, Jimenez-Baranda S, Mira E, et al. Statins inhibit HIV-1 infection by down-regulating Rho activity. J Exp Med 2004; 200:541-7. (Pubitemid 39121911)
7. Iyengar S, Hildreth JE, Schwartz DH. Actin-dependent receptor co-localization required for human immunodeficiency virus entry into host cells. J Virol 1998; 72:5251-5. (Pubitemid 28215709)
8. Giguere JF, Tremblay MJ. Statin compounds reduce human immunodeficiency virus type 1 replication by preventing the interaction between virion-associated host intercellular adhesion molecule 1 and its natural cell surface ligand LFA-1. J Virol 2004; 78:12062-5. (Pubitemid 39390792)
9. Gilbert C, Bergeron M, Methot S, Giguere JF, Tremblay MJ. Statins could be used to control replication of some viruses, including HIV-1. Viral Immunol 2005; 18:474-89.
10. Jain MK, Ridker PM. Anti-inflammatory effects of statins: clinical evidence and basic mechanisms. Nat Rev Drug Discov 2005; 4:977-87.
11. Probasco JC, Spudich SS, Critchfield J, et al. Failure of atorvastatin to modulate CSF HIV-1 infection: results of a pilot study. Neurology 2008; 71:521-4.
12. Sklar PA, Masur H, Grubb JR, et al. Pravastatin does not have a consistent antiviral effect in chronically HIV-infected individuals on antiretroviral therapy. AIDS 2005; 19:1109-11. (Pubitemid 40961155)
13. Waters L, Stebbing J, Jones R, et al. The effect of statins on HIV rebound and blips. J Acquir Immune Defic Syndr 2005; 39:637-8. (Pubitemid 41098484)
14. Moncunill G, Negredo E, Bosch L, et al. Evaluation of the anti-HIV activity of statins. AIDS 2005; 19:1697-700. (Pubitemid 41502686)
15. Ojesina AI, Chaplin B, Sankale JL, et al. Interplay of reverse transcriptase inhibitor therapy and gag p6 diversity in HIV type 1 subtype G and CRF02-AG. AIDS Res Hum Retroviruses 2008; 24:1167-74.
16. Dewar RL, Highbarger HC, Sarmiento MD, et al. Application of branched DNA signal amplification to monitor human immunodeficiency virus type 1 burden in human plasma. J Infect Dis 1994; 170:1172-9. (Pubitemid 24328620)
17. Friedman LM, Furberg CD, Demets DL. Fundamentals of clinical trials. Littleon, MA: John Wright PSG Inc, 1983.
18. Berry PH, MacDonald JS, Alberts AW, et al. Brain and optic system pathology in hypocholesterolemic dogs treated with a competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase. Am J Pathol 1988; 132:427-43.
19. + T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis 2003; 187:1534-43.
20. Margolick JB, Volkman DJ, Folks TM, Fauci AS. Amplification of HTLV-III/LAV infection by antigen-induced activation of T cells and direct suppression by virus of lymphocyte blastogenic responses. J Immunol 1987; 138:1719-23. (Pubitemid 17040792)
21. Weitz-Schmidt G. Lymphocyte function-associated antigen-1 blockade by statins: molecular basis and biological relevance. Endothelium 2003; 10:43-7. (Pubitemid 36355982)
22. Guijarro C, Blanco-Colio LM, Ortego M, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res 1998; 83:490-500. (Pubitemid 28411050)
23. Poli A. Atorvastatin: pharmacological characteristics and lipid-lowering effects. Drugs 2007; 67(suppl 1):3-15.
24. Pfizer. Lipitor (atorvastatin calcium) tablets for oral administration prescribing information. www.pfizer.com/files/products/uspi-lipitor.pdf. Accessed 5 January 2011.
25. Borek-Dohalsky V, Huclova J, Barrett B, Nemec B, Ulc I, Jelinek I. Validated HPLC-MS-MS method for simultaneous determination of atorvastatin and 2-hydroxyatorvastatin in human plasma-pharmacokinetic study. Anal Bioanal Chem 2006; 386:275-85. (Pubitemid 44327024)
26. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-70. (Pubitemid 29159331)
27. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-33.
28. Ganesan A, Chattopadhyay PK, Brodie TM, et al. Immunologic and virologic events in early HIV infection predict subsequent rate of progression. J Infect Dis 201:272-84.
29. Rodger AJ, Fox Z, Lundgren JD, et al. Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection. J Infect Dis 2009; 200:973-83.
30. Gupta SK, Komarow L, Gulick RM, et al. Proteinuria, creatinine clearance, and immune activation in antiretroviral-naive HIV-infected subjects. J Infect Dis 2009; 200:614-8.
31. Crowe SM, Westhorpe CL, Mukhamedova N, Jaworowski A, Sviridov D, Bukrinsky M. The macrophage: the intersection between HIV infection and atherosclerosis. J Leukoc Biol 87:589-98.
32. Greenwood J, Steinman L, Zamvil SS. Statin therapy and autoimmune disease: from protein prenylation to immunomodulation. Nat Rev Immunol 2006; 6:358-70.
33. Kwak B, Mulhaupt F, Myit S, Mach F. Statins as a newly recognized type of immunomodulator. Nat Med 2000; 6:1399-402. (Pubitemid 32001026)
34. Weitz-Schmidt G, Welzenbach K, Brinkmann V, et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med 2001; 7:687-92. (Pubitemid 32588024)
35. + T cells. Atherosclerosis 2008; 197:829-39.
36. Methe H, Kim JO, Kofler S,Nabauer M,Weis M. Statins decrease Toll-like receptor 4 expression and downstream signaling in human CD14+ monocytes. Arterioscler Thromb Vasc Biol 2005; 25:1439-45. (Pubitemid 40923365)
37. Niessner A, Steiner S, Speidl WS, et al. Simvastatin suppresses endotoxin-induced upregulation of Toll-like receptors 4 and 2 in vivo. Atherosclerosis 2006; 189:408-13. (Pubitemid 44634488)
38. Mulhaupt F, Matter CM, Kwak BR, et al. Statins (HMG-CoA reductase inhibitors) reduce CD40 expression in human vascular cells. Cardiovasc Res 2003; 59:755-66. (Pubitemid 38368692)
39. Yoshida M, Sawada T, Ishii H, et al. Hmg-CoA reductase inhibitor modulates monocyte-endothelial cell interaction under physiological flow conditions in vitro: involvement of Rho GTPase-dependent mechanism. Arterioscler Thromb Vasc Biol 2001; 21:1165-71. (Pubitemid 34215145)
40. Schonbeck U, Libby P. Inflammation, immunity, and HMG-CoA reductase inhibitors: statins as antiinflammatory agents? Circulation 2004; 109:II18-26.
41. Tong-Starksen SE, Luciw PA, Peterlin BM. Human immunodeficiency virus long terminal repeat responds to T cell activation signals. Proc Natl Acad Sci U S A 1987; 84:6845-9.
42. Diomede L, Albani D, Sottocorno M, et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol 2001; 21:1327-32.
43. + T cells using a combination of cytokines. J Exp Med 1998; 188:83-91.
44. Rizzardi GP, Harari A, Capiluppi B, et al. Treatment of primary HIV-1 infection with cyclosporin A coupled with highly active antiretroviral therapy. J Clin Invest 2002; 109:681-8. (Pubitemid 34204847)
45. Vermeulen JN, Prins JM, Bunnik E, et al. Intravenous immunoglobulin (IVIG) treatment for modulation of immune activation in human immunodeficiency virus type 1 infected therapy-naive individuals. AIDS Res Hum Retroviruses 2007; 23:1348-53.
46. Lederman MM, Smeaton L, Smith KY, et al. Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. J Infect Dis 2006; 194:1677-85. (Pubitemid 44901998)
47. Link A, Ayadhi T, Bohm M, Nickenig G. Rapid immunomodulation by rosuvastatin in patients with acute coronary syndrome. Eur Heart J 2006; 27:2945-55. (Pubitemid 44950437)
48. Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
49. Ray KK, Cannon CP, McCabe CH, et al. Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial. J Am Coll Cardiol 2005; 46:1405-10. (Pubitemid 41446173)